1. Home
  2. LMAT vs TRVI Comparison

LMAT vs TRVI Comparison

Compare LMAT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$83.21

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$11.31

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
TRVI
Founded
1983
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.5B
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
LMAT
TRVI
Price
$83.21
$11.31
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$101.83
$20.38
AVG Volume (30 Days)
177.9K
1.8M
Earning Date
02-26-2026
11-13-2025
Dividend Yield
0.96%
N/A
EPS Growth
27.40
N/A
EPS
2.32
N/A
Revenue
$240,866,000.00
N/A
Revenue This Year
$15.17
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$36.00
N/A
Revenue Growth
13.07
N/A
52 Week Low
$71.42
$3.47
52 Week High
$105.55
$14.39

Technical Indicators

Market Signals
Indicator
LMAT
TRVI
Relative Strength Index (RSI) 50.05 37.18
Support Level $79.40 $10.58
Resistance Level $86.00 $13.16
Average True Range (ATR) 2.22 0.64
MACD 0.06 -0.24
Stochastic Oscillator 49.69 27.27

Price Performance

Historical Comparison
LMAT
TRVI

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: